Cited 3 times in
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.